severe osteoporosis
Conditions
Interventions
Denosumab sequential Teriparatide group (T group):NA
Denosumab sequential zoledronic acid group (T group):NA
Denosumab group alone (Group D):NA
Sponsors
The Second People's Hospital of Hefei
Eligibility
Sex/Gender
All
Age
60 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1.The male patient was over 60 years old and the female patient was postmenopausal; 2.All enrolled patients were diagnosed with "severe osteoporosis" by the DR Image-based osteoporosis intelligent assisted screening system and dual-energy X-ray absorptiometry. The classification of bone mineral density measured by DXA is as follows: Normal: T value = -1.0; Decreased bone mass: -2.5 < T value < -1.0; Osteoporosis: T value = -2.5; Severe osteoporosis: T-score = -2.5 with a history of fragility fractures;
Exclusion criteria
Exclusion criteria: 1.There are other diseases that affect bone metabolism, such as rheumatic immune system diseases, endocrine metabolic diseases, and malignant tumor diseases; 2.There is a recent history of other drug use that can affect bone metabolism, such as long-term use of hormone drugs; 3.The presence of L1-L4 or bilateral hip fixation (including bone cement, artificial bone, metal implant, etc.);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| bone mineral density,BMD; | — |
Secondary
| Measure | Time frame |
|---|---|
| bone metabolic markers; | — |
Countries
China
Contacts
Public ContactChu Jianjun
The Second People's Hospital of Hefei
Outcome results
None listed